168 related articles for article (PubMed ID: 18181189)
21. IR microspectroscopy: potential applications in cervical cancer screening.
Walsh MJ; German MJ; Singh M; Pollock HM; Hammiche A; Kyrgiou M; Stringfellow HF; Paraskevaidis E; Martin-Hirsch PL; Martin FL
Cancer Lett; 2007 Feb; 246(1-2):1-11. PubMed ID: 16713674
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of p16 for differentiating primary pulmonary squamous cell carcinoma from cervical squamous cell carcinoma metastatic to the lung.
Wang CW; Wu TI; Yu CT; Wu YC; Teng YH; Chin SY; Lai CH; Chen TC
Am J Clin Pathol; 2009 May; 131(5):715-22. PubMed ID: 19369633
[TBL] [Abstract][Full Text] [Related]
23. A study of cervical cancer screening for prevention of carcinoma cervix.
Christe DM; Mohanambal M; Ramamurthy V; Snehaa NB
J Indian Med Assoc; 2008 Dec; 106(12):779-80, 782. PubMed ID: 19370947
[TBL] [Abstract][Full Text] [Related]
24. [Detection of multiple human papillomavirus infection in cervical specimens by flow fluorescent hybridization].
Chen QY; Bian ML; Zhang XY; Ou H; Ma L
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):901-5. PubMed ID: 19671291
[TBL] [Abstract][Full Text] [Related]
25. Human papillomavirus testing for primary cervical cancer screening.
Grce M; Davies P
Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
[TBL] [Abstract][Full Text] [Related]
26. Integrating human papillomavirus vaccination in cervical cancer control programmes.
Franco EL; Coutlée F; Ferenczy A
Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
[TBL] [Abstract][Full Text] [Related]
27. Identification of candidate biomarker proteins released by human endometrial and cervical cancer cells using two-dimensional liquid chromatography/tandem mass spectrometry.
Li H; DeSouza LV; Ghanny S; Li W; Romaschin AD; Colgan TJ; Siu KW
J Proteome Res; 2007 Jul; 6(7):2615-22. PubMed ID: 17523614
[TBL] [Abstract][Full Text] [Related]
28. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
[TBL] [Abstract][Full Text] [Related]
29. Assessing new technologies for cervical cancer screening: beyond sensitivity.
Massad LS
J Low Genit Tract Dis; 2008 Oct; 12(4):311-5. PubMed ID: 18820547
[TBL] [Abstract][Full Text] [Related]
30. Objective screening for cervical cancer in developing nations: lessons from Nigeria.
Roblyer D; Richards-Kortum R; Park SY; Adewole I; Follen M
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S94-7. PubMed ID: 17825396
[TBL] [Abstract][Full Text] [Related]
31. Application of malignancy-associated changes of the cervical epithelium in a hierarchic classification concept.
Haroske G; Bergander S; König R; Meyer W
Anal Cell Pathol; 1990 Apr; 2(3):189-98. PubMed ID: 2275865
[TBL] [Abstract][Full Text] [Related]
32. Cervical cancer screening in medically underserved California Latina and non-Latina women: effect of age and regularity of Pap testing.
Howell LP; Gurusinghe S; Tabnak F; Sciortino S
Cancer Detect Prev; 2009; 32(5-6):372-9. PubMed ID: 19264426
[TBL] [Abstract][Full Text] [Related]
33. Molecular biomarkers in cervical cancer diagnosis: a critical appraisal.
Litjens RJ; Hopman AH; van de Vijver KK; Ramaekers FC; Kruitwagen RF; Kruse AJ
Expert Opin Med Diagn; 2013 Jul; 7(4):365-77. PubMed ID: 23777477
[TBL] [Abstract][Full Text] [Related]
34. [Flow & image cytometry and clinical applications in cancer diagnosis].
Nishiya I; Izutsu T
Rinsho Byori; 1993 Jun; Suppl 94():51-65. PubMed ID: 8361009
[No Abstract] [Full Text] [Related]
35. [Usefulness of HPV test on cell sample from the cervix].
Vintermyr OK; Skar R; Iversen OE; Haugland HK
Tidsskr Nor Laegeforen; 2008 Jan; 128(2):171-3. PubMed ID: 18202727
[TBL] [Abstract][Full Text] [Related]
36. Assessment of new technologies for cervical cancer screening.
Villa LL
Lancet Oncol; 2008 Oct; 9(10):910-1. PubMed ID: 19071241
[No Abstract] [Full Text] [Related]
37. Assessment of data pre-processing methods for LC-MS/MS-based metabolomics of uterine cervix cancer.
Chen Y; Xu J; Zhang R; Shen G; Song Y; Sun J; He J; Zhan Q; Abliz Z
Analyst; 2013 May; 138(9):2669-77. PubMed ID: 23486772
[TBL] [Abstract][Full Text] [Related]
38. Malignant cell detection and cervical cancer screening.
Bacus JW; Wiley EL; Galbraith W; Marshall PN; Wilbanks GD; Weinstein RS
Anal Quant Cytol; 1984 Jun; 6(2):121-30. PubMed ID: 6465697
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls.
Dong HP; Holth A; Berner A; Davidson B; Risberg B
Cytometry B Clin Cytom; 2007 Sep; 72(5):332-43. PubMed ID: 17226863
[TBL] [Abstract][Full Text] [Related]
40. Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery.
Habis AH; Vernon SD; Lee DR; Verma M; Unger ER
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):492-6. PubMed ID: 15006929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
